(The 3rd CIIE) Innovative anti-influenza drugs attract attention at CIIE, strong grassroots chronic disease management and start the "Combination of Peace and War"
China News Service, November 10 (Reporter Chen Jing) At the 3rd CIIE held under the normalization of epidemic prevention and control, the attention of all walks of life to influenza has increased significantly.
The reporter learned on the 10th that Xofluza (mabaloxavir), an anti-flu drug with an innovative mechanism, has attracted a lot of attention.
Roche's Xofluza is currently the first and only single-dose oral drug approved to treat influenza.
Professor Hu Bijie, director of the Department of Infectious Diseases at Zhongshan Hospital, Fudan University, introduced that patients only need to take Xofluza once for the entire course of the disease to shorten the time for flu symptom relief; and after the medication, the flu virus can be controlled and eliminated within 24 hours, which greatly reduces the duration of symptoms .
Chen Erzhen said that this winter, there may be a dual risk of new coronary pneumonia and influenza pandemic. It is particularly important for the public to strengthen their awareness of influenza and other acute respiratory infectious diseases and standardize prevention.
Photo courtesy of Roche Pharmaceuticals
Professor Chen Erzhen, deputy dean of Ruijin Hospital affiliated to Shanghai Jiaotong University School of Medicine, said in an interview that there may be a dual risk of new coronary pneumonia and influenza pandemic this winter, and it is particularly important for the public to strengthen awareness of influenza and other acute respiratory infectious diseases and standard prevention.
It is understood that many people mistake the flu for the common cold.
In fact, influenza is a kind of infectious respiratory disease caused by influenza virus. It is mainly spread by droplets and contact. Once high-risk groups are infected, they are prone to complications and aggravate the disease.
Hu Bijie told reporters: “Children, adolescents, and the elderly are high-risk groups that are vulnerable to influenza attacks.” He urged that once people develop flu-like symptoms, such as fever, headache, myalgia, and general malaise, they must grasp the “first” of treatment. One time", received antiviral treatment within 48 hours of onset.
At present, chronic disease has become a major threat to the health of the Chinese people.
At the 3rd CIIE, French medical and health company Sanofi's new lipid-lowering drug Alixiumab injection attracted the attention of the audience.
It is understood that in China, Alixizumab injection has been approved for two major indications at the same time.
Professor Ben He from the Department of Cardiology, Shanghai Chest Hospital bluntly stated that the blood lipid management program in China's previous clinical practice is relatively conservative. Even if many patients have taken lipid-lowering drugs, their blood lipid levels still cannot reach the target.
He said that Alixizumab injection not only has a strong lipid-lowering effect, but also has been recognized by many clinical experts in reducing the risk of cardiovascular events.
Hu Bijie called for people to receive antiviral treatment within 48 hours of the onset of flu-like symptoms.
Photo courtesy of Roche Pharmaceuticals
Professor Ben He said in an interview that the long-term follow-up of patients with acute coronary syndrome in China is not ideal, and the patients have poor compliance with long-term medication.
Subcutaneous injection of Aliciyuumab injection every two weeks is beneficial to improve patient compliance.
The expert hopes that innovative lipid-lowering drugs can be included in the medical insurance catalog.
During the interview, the reporter learned that Sanofi not only brought many innovative treatment solutions to the exhibition, but also brought new models and new explorations to the grassroots chronic disease management.
It is understood that the China Chronic Disease Collaborative Management System Construction Project (referred to as the "Chronic Disease Synergy Project") was launched, and extensive and in-depth investigations were conducted on the status of chronic disease diagnosis and treatment in 500 county hospitals.
As the main supporter, Sanofi has further enhanced the management of chronic diseases through accumulated technology and management experience, coordinated with the top and bottom, and actively participated in exploring the construction of chronic disease management throughout the life cycle.
Preliminary research results show that the compact county medical community is one of the main models of chronic disease management at the grassroots level in the future, which can effectively realize the hierarchical diagnosis and management of patients; it should be further improved through the construction of specialized diagnosis and treatment centers related to chronic disease management and the linkage between counties and townships Basic level of diagnosis and treatment.
Professor Kong Lingzhi, Director of the Executive Committee of the Chronic Disease Consortium Project, told reporters: "The development of the Chronic Disease Consortium Project officially opened the construction of a new model that combines peacetime and emergency conditions. It has entered into multi-sectoral collaborative support, full-process co-management, government and A full-life cycle management model with the participation of social resources from all walks of life; this project will provide important decision-making basis for policy making in the field of chronic diseases in China."
He Ben hopes that innovative lipid-lowering drugs can be included in the medical insurance catalog.
Photo courtesy of Sanofi
Many multinational pharmaceutical companies have their own plans for the management of chronic diseases in China.
Novo Nordisk Global President and CEO Zhou Fude said that the development and application of the digital field in the future is very important for diabetic patients.
At present, the company is trying to apply digital technology to insulin injections. It only needs to adjust relevant information to achieve precise injections.
Being overweight is an important cause of diabetes.
Zhou Fude revealed that the next step will be to develop drugs to fight obesity.
Dr. He Enting, General Manager and President of China of Sanofi Pharmaceuticals Global Business Unit, said: “Continuously improving the health of the Chinese people through high-quality drugs and innovative diagnosis and treatment programs is an important part of the company’s strategy.” In the future, the company will continue to work closely with all sectors of society to build a life-cycle chronic disease management for patients, and help achieve Healthy China 2030.
(Finish)